About ANNEXON, INC.
Annexon Biosciences is a biotechnology company focused on developing first-in-class therapies targeting the classical complement pathway to treat autoimmune, neurodegenerative, and ophthalmic diseases. The company was co-founded by Dr. Ben Barres, a former Chair of Neurobiology at Stanford University.
Development of C1q blocking antibodies for treating complement-driven diseasesResearch on neuron-glial interactions in the central nervous systemPipeline of early complement inhibitors targeting diseases of the body, brain, and eye
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ANNEXON, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.